GLP-1 weight loss claims on TikTok: what the data says

What's this video probably claiming?

Creator @balance.with.hannah is almost certainly running a GLP-1 affiliate promotion, given the discount code format ('CODE HANNAH saves you 100') and the injection emoji. Based on the category tag and creator patterns common in this space, the video likely covers some combination of personal weight loss results on semaglutide or tirzepatide, claims about appetite suppression, energy changes, or blood sugar stabilization, and a pitch toward a compounded or telehealth-sourced GLP-1 product. Creators in this niche frequently frame their experience as broadly representative, suggest rapid or dramatic outcomes are typical, and downplay the clinical requirements for these medications. The '$100 off' hook is a textbook affiliate structure, which does not automatically mean the claims are wrong, but it does mean there's a financial incentive baked into every statement made in the video.

What does the science actually show?

GLP-1 receptor agonists have a genuinely strong evidence base. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg weekly produced mean body weight reduction of 14.9% over 68 weeks in adults with obesity but without diabetes. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide at 15 mg produced up to 20.9% mean weight loss over 72 weeks. These are real, large, randomized controlled trials with placebo arms. What they also show, and what TikTok creators reliably omit: most participants regained significant weight within a year of stopping medication (STEP 4 data, Rubino et al., 2021, NEJM). Side effects including nausea, vomiting, and gastroparesis-like symptoms were common. These drugs work, but they work in specific clinical contexts, at specific doses, under medical supervision.

Where does the social media noise diverge from clinical reality?

The gap between TikTok GLP-1 content and clinical reality is wide and specific. First, individual results shown by creators are almost always outliers or, at minimum, unrepresentative of the trial averages. Second, there's a persistent conflation between compounded semaglutide or tirzepatide (what many telehealth platforms dispense) and FDA-approved brand-name drugs like Wegovy or Zepbound. These are not the same product under federal law, and FormBlends does not claim equivalency. Third, the 'I stopped feeling hungry completely' narrative ignores that around 10-20% of trial participants experienced significant GI adverse events requiring dose adjustment or discontinuation. Fourth, codes and affiliate links tied to regulated medications raise real questions about whether the creator is subject to FTC disclosure requirements and whether the platform they're promoting is operating compliantly. The FDA has flagged compounded GLP-1 supply chains repeatedly since 2023.

What should you actually know?

If you're considering a GLP-1 medication, the clinical evidence supports meaningful weight loss for people with a BMI of 30 or above, or 27 or above with a weight-related comorbidity. That's the FDA-cleared indication. A TikTok discount code is not a medical consultation. Actual prescribing requires a licensed provider to review your history, current medications, and contraindications, including personal or family history of medullary thyroid carcinoma, which carries a boxed warning for this drug class. Cost matters too: brand-name GLP-1 drugs run $900 to $1,300 per month without insurance coverage. Compounded alternatives are cheaper but sit in a legally different category. Anyone promoting these medications via affiliate code should be disclosing that relationship clearly. Watch for red flags: before-and-after photos with no timeline context, claims of zero side effects, and zero mention of the need for ongoing medical oversight.